Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2006 | Original Paper

Decreased galectin-3 expression during the progression of cervical neoplasia

Authors: Jeong-Won Lee, Sang Yong Song, Jung-Joo Choi, Chel Hun Choi, Tae-Joong Kim, Jhingook Kim, Je-Ho Lee, Byoung-Gie Kim, Duk-Soo Bae

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2006

Abstract

Purpose: Galectin-3 is expressed widely in epithelial and immune cells and the level of expression varies in many cancer cells relative to the normal tissues from which they arise. We investigated whether the expression of galectin-3 is associated with the progression of cervical neoplasia. Methods: Galectin-3 expression was evaluated in fresh frozen tissues of cervical carcinoma using real-time quantitative RT-PCR. In addition, galectin-3 expression was evaluated at the protein level by immunohistochemistry in 90 formalin-fixed paraffin-embedded cervical tissues, 10 normal cervical specimens, 20 low-grade squamous intraepithelial lesions (LSILs), 20 high-grade squamous intraepithelial lesions (HSILs), and 40 invasive squamous cell carcinomas (ISCCs). Results: Real-time quantitative RT-PCR revealed that galectin-3 expressions in tumor cells were significantly downregulated compared with corresponding normal tissue (P=0.005). Moreover, immunohistochemistry showed that galectin-3 expression was strong in all normal cervical squamous epithelia and gradually decreased in accordance with the histopathologic grades in order LSIL > HSIL > ISCC (P<0.001). Conclusions: These data constitute the first observation that the expression of galectin-3 is downregulated in cervical cancer tissues and suggest that the decreased expression of this galactoside-binding lectin is associated with the progression of cervical neoplasia.

Albrandt K, Orida NK, Liu FT (1987) An IgE-binding protein with a distinctive repetitive sequence and homology with an IgG receptor. Proc Natl Acad Sci USA 84:6859–6863PubMedCrossRef

Barondes SH, Cooper DN, Gitt MA, Leffler H (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807–20810PubMed

Berberat PO, Friess H, Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A, Buchler MW (2001) Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 49:539–549PubMed

Bresalier RS, Byrd JC, Wang L, Raz A (1996) Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. Cancer Res 56:4354–4357PubMed

Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, Raz A (1998) Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 115:287–296PubMedCrossRef

van den Brule FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V (1994) Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30A:1096–1099PubMedCrossRef

van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V (1996) Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27:1185–1191PubMedCrossRef

Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, Liu FT, Fernandez PL, Sobel ME (1992) Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 84:1161–1169PubMedCrossRef

Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C, Sobel ME (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179:43–48PubMedCrossRef

Dagher SF, Wang JL, Patterson RJ (1995) Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA 92:1213–1217PubMedCrossRef

Danguy A, Camby I, Kiss R (2002) Galectins and cancer. Biochim Biophys Acta 1572:285–293PubMed

Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:329–337PubMedCrossRef

Delorge S, Saussez S, Pelc P, Devroede B, Marchant H, Burchert M, Zeng FY, Danguy A, Salmon I, Gabius HJ, Kiss R, Hassid S (2000) Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg 122:834–841PubMed

DiSaia PJ, Creasman WJ (2002) Preinvasive disease of the cervix. In: Clinical gynecologic oncology, 6th edn. Mosby, St. Louis, pp 1–34

Francois C, van Velthoven R, De Lathouwer O, Moreno C, Peltier A, Kaltner H, Salmon I, Gabius HJ, Danguy A, Decaestecker C, Kiss R (1999) Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 112:194–203PubMed

Frigeri LG, Zuberi RI, Liu FT (1993) Epsilon BP, a beta-galactoside-binding animal lectin, recognizes IgE receptor (Fc epsilon RI) and activates mast cells. Biochemistry (Moscow) 32:7644–7649CrossRef

Fukao S, McClure JP, Ito A, Sato T, Kimura I, Tsuda T, Kato S (1999) 1st VHF radar observation of midlatitude F-region field-aligned irregularities. Geophys Res Lett 15:768CrossRef

Inohara H, Raz A (1995) Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 55:3267–3271PubMed

Inohara H, Akahani S, Koths K, Raz A (1996) Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 56:4530–4534PubMed

Irimura T, Matsushita Y, Sutton RC, Carralero D, Ohannesian DW, Cleary KR, Ota DM, Nicolson GL, Lotan R (1991) Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 51:387–393PubMed

Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E, Gabius HJ (2001) Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 127:375–386PubMedCrossRef

Lindstedt R, Apodaca G, Barondes SH, Mostov KE, Leffler H (1993) Apical secretion of a cytosolic protein by Madin-Darby canine kidney cells. Evidence for polarized release of an endogenous lectin by a nonclassical secretory pathway. J Biol Chem 268:11750–11757PubMed

Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R (2003) HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 101:433–440PubMedCrossRef

Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E (1994) Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56:474–480PubMedCrossRef

Lotz MM, Andrews CW Jr, Korzelius CA, Lee EC, Steele GD Jr, Clarke A, Mercurio AM (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90:3466–3470PubMedCrossRef

Moutsatsos IK, Wade M, Schindler M, Wang JL (1987) Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci USA 84:6452–6456PubMedCrossRef

Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899–909PubMed

Ohannesian DW, Lotan D, Thomas P, Jessup JM, Fukuda M, Gabius HJ, Lotan R (1995) Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55:2191–2199PubMed

Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, Pazerini G, Carmi P (1990) Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 46:871–877PubMedCrossRef

Richards M, Tan S, Fong CY, Biswas A, Chan WK, Bongso A (2003) Comparative evaluation of various human feeders for prolonged undifferentiated growth of human embryonic stem cells. Stem Cells 21:546–556PubMedCrossRef

Richart RM (1990) A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol 75:131–133PubMed

Sahin A, Abokhodair A (1998) Geostatistical approach in design of sampling patterns for Jabal–Sayid sulfide deposit, Western Saudi-Arabia. J Afr Earth Sci Middle East 8:40–42

Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A, Campo E (1997) Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113:1906–1915PubMedCrossRef

Schoeppner HL, Raz A, Ho SB, Bresalier RS (1995) Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75:2818–2826PubMedCrossRef

Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, Furukawa H, Nagashima M, Yoshino S, Mabuchi A, Sekine A, Saito S, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35:341–348PubMedCrossRef

Woo HJ, Joo HG, Song SW, Sohn YS, Chae C (2001) Immunohistochemical detection of galectin-3 in canine gastric carcinomas. J Comp Pathol 124:216–218PubMedCrossRef

Xu XC, el-Naggar AK, Lotan R (1995) Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147:815–822PubMed

Yu F, Finley RL, Jr, Raz A, Kim HR (2002) Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 277:15819–15827PubMedCrossRef

Title: Decreased galectin-3 expression during the progression of cervical neoplasia
Authors: Jeong-Won Lee
Sang Yong Song
Jung-Joo Choi
Chel Hun Choi
Tae-Joong Kim
Jhingook Kim
Je-Ho Lee
Byoung-Gie Kim
Duk-Soo Bae
Publication date: 01-04-2006
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2006
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-005-0069-1

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Decreased galectin-3 expression during the progression of cervical neoplasia

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2006

Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer

Short-term monitoring of cognitive functions before and during the first course of treatment

Clinical significance of a wide excision policy for sacrococcygeal chordoma

Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers

Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page